For research use only. Not for therapeutic Use.
Vobarilizumab（Cat No.:I042212）is a monoclonal antibody that targets the IL-4 receptor alpha (IL-4Rα), which is involved in immune system regulation and inflammation. By inhibiting IL-4Rα, vobarilizumab aims to block the signaling of both IL-4 and IL-13, cytokines that play a role in various inflammatory and autoimmune diseases, including asthma, atopic dermatitis, and other allergic conditions. The drug is being investigated in clinical trials to assess its safety and efficacy in treating these conditions, with the goal of reducing inflammation and improving symptom control in patients with chronic inflammatory diseases.
| CAS Number | 1628814-88-9 |
| Purity | ≥95% |
